ClinicalTrials.gg
RecruitingNCT07578012PIRTIKUpdated Jul 8, 2026

Prevention With Ismigen of RTIs in Kids

A Phase 4 interventional study of Bacterial Lysates and Placebo in Respiratory Tract Infections (RTI) and Healthy Children, sponsored by Lallemand Pharma AG. Recruiting at 10 sites in Poland. Open to participants aged 3 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Lallemand Pharma AG · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Respiratory Tract Infections with a site in Poland — 2 open to participants now, 3 under way, 1 of them phase 3. Respiratory Tract Infections · Poland.

Planned enrollment
7th of 18
224 · median 154
Started
2026
with 1 other
Phase 4
3 of 20
1 open now
Registered
20th of 20
by date
Lead sponsor
1 of 20
Lallemand Pharma AG

Among the 20 studies in Respiratory Tract Infections with a site in Poland, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 4, and was the 20th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

2 of the 20 studies in Respiratory Tract Infections with a site in Poland are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 3 Years to 12 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Respiratory Tract Infections with a site in Poland, or all of them as a file.
02

Study summary

Although the efficacy of PMBL® sublingual tablets is evident to most prescribers, the clinical studies available to demonstrate the efficacy of this bacterial lysate in preventing recurrent respiratory tract infections have undeniable methodological biases. To demonstrate the efficacy of PMBL® in the pediatric population without questionable bias, a randomized double-blind Placebo-controlled study will be conducted: one arm of children presenting with a risk of recurrent respiratory tract infections will be treated with PMBL® for a 3-month period, 10 days per months during the fall-winter whereas subjects of the Placebo arm will receive sublingual tablet indistinguishable from PMBL® but without active ingredients. Both groups of subjects will be followed for four additional months. To improve the accuracy of data and the tracking of respiratory tract infections (RTI), a diary will be provided to each subject, allowing them to report the event as soon as it occurs. If necessary, a visit may be planned to enable the investigator to assess the event accurately.

Read the detailed description

Respiratory tract infections (RTIs) are the leading cause of acute disease incidence worldwide that affect people of all ages. They are usually caused by viral pathogens, the most common of which including rhinoviruses, coronaviruses, adenoviruses, respiratory syncytial virus and influenza viruses. Bacterial pathogens can also cause RTIs, but they are less common. Various studies show the seasonality of RTIs. Influenza tends to occur in late autumn and winter, while other RTIs have a much more diffuse occurrence throughout the year. Although RTIs are usually not life-threatening, they significantly decrease quality of life and represent a substantial proportion of healthcare visits, mainly in women and young children, contributing to a financial burden on society.

Ismigen® (Polyvalent Mechanical Bacterial Lysate; PMBL) which is manufactured by mechanical lysis is currently authorized in two EU Member States (MS), Italy and Poland, where Lallemand Pharma Europe is the Marketing Authorization Holder (MAH) as sublingual tablets for the prophylaxis of recurrent RTI in adults. It is authorized in Poland in children from 3 years of age.

On 27 June 2019, the European Medicines Agency (EMA) recommended that bacterial lysates-containing medicinal products authorized for respiratory conditions should only be used for the prevention of recurrent respiratory tract infections, with the exception of pneumonia. This followed a review in which EMA's human medicines committee (CHMP) considered the results of clinical studies, data on side effects reported with these medicines, and advice from an expert group on infectious diseases. Although data are limited, the review found some evidence of effectiveness of bacterial lysates in the prevention of recurrent RTI together with a safety profile in line with what is expected for this type of product. The CHMP therefore recommended that use of bacterial lysates for prevention can continue, but the companies must provide further data on safety and effectiveness by Q1 2026 through the conduct of phase IV double-blind, multicenter, RCTs in this indication.

The present study is a Post-Authorization Efficacy Study (PAES) designed to demonstrate that PMBL® sublingual tablet used according to the SmPC instructions can reduce the incidence of respiratory tract infections in children 3 to 12 years old during the fall and winter period when compared to a matched Placebo.

03

Conditions studied

  • Respiratory Tract Infections (RTI)
  • Healthy Children

Keywords

  • Respiratory Tract Infections (RTI)
  • Bacterial Lysates
  • PMBL® sublingual tablets
  • Recurrent Respiratory Tract Infections
  • Ismigen
  • Incidence
04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children of both genders aged from 3 to 12 years.
  2. Written obtained from the parents/legally authorized representatives
  3. Written assent obtained from the subject from 7 years
  4. Subject presenting with a susceptibility to respiratory tract infections according to the investigator
  5. No respiratory tract infection within 15 days before the randomization visit
  6. All girls of have a negative pregnancy urine testing at randomization visit and are informed and their parents as well of the requirement for during the study.
  7. A cooperative attitude and ability to correct use of PMBL® tablet.

Exclusion criteria

Exclusion Criteria:

  1. Subject treated with bacterial lysates within the previous 6 months prior to V1 or ongoing treatment.
  2. Body temperature ≥ 37.5°C at the randomization visit.
  3. Pregnant/Lactating female or with sexual activity without hormonal , intrauterine device or barrier methods.
  4. Primary or secondary immunodeficiency, cystic fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency, , endocrinological diseases or other chronic respiratory diseases, except asthma and allergic rhinitis.
  5. Known sensitivity to the components of study medication.
  6. Any major surgery within the last 3 months prior to study enrolment or planned to occur within the duration of study.
  7. Treatment with the following medications:

    1. Injection or oral administration of within 4 weeks prior to study enrolment.
    2. Previous and/or concomitant , immunostimulants, allergen-immunotherapy or gamma globulins within 6 months prior to study enrolment.
  8. Inability to understand or comply with study procedures or with study treatment intake.
  9. Subject participating in another interventional clinical study at the time of screening visit.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
224 participants (estimated)

Study arms

  • Active comparator
    PMBL® sublingual tablet

    Ismigen® (Polyvalent Mechanical Bacterial Lysate; PMBL) is a sublingual tablet marketed by Lallemand Pharma Europe. Each tablet contains: * Lyophilised bacterial lysate 50 mg * Excipients q.s. 250mg The posology of Ismigen® for paediatric population (from 3 years of age) is one tablet per day before food, to be dissolved under the tongue. Use for ten consecutive days per month, over a period of 3 months.

    Drug: Bacterial Lysates

  • Placebo comparator
    Placebo

    The comparator is a sublingual tablet, indistinguishable from the investigational product. Each tablet of placebo comparator has the same composition as the investigational medicinal product being tested (with the exception of the active substance, which is replaced by glycine (7 mg)). Posology, instructions for use, contraindications, precautions of use and labelling are identical to those for Ismigen®. The posology of Placebo is one tablet per day before food, to be dissolved under the tongue. Use for ten consecutive days per month, over a period of 3 months.

    Drug: Placebo

Interventions

  • 3-month period, 10 days per months during the fall-winter

    Also known as: PMBL® sublingual tablet, ISMIGEN®

  • DrugPlacebo

    3-month period, 10 days per months during the fall-winter

06

What researchers measure

Primary outcomes

  1. The total number of RTIs experienced by each subject throughout the 7-month study period (3-month treatment + 4-month follow-up).

    Rate of Respiratory Tract Infections (RTIs): the number of RTIs experienced by a subject throughout the study (3 month-treatment period and 4 month-follow-up) will be assessed.

    Time frame: Throughout the 7-month study period (3-month treatment + 4-month follow-up).

Secondary outcomes

  1. Mean duration in days per RTI during the overall study period.

    Estimated treatment effect from MMRM with 95% CI.

    Time frame: Throughout the 7-month study period (3-month treatment + 4-month follow-up).

  2. Number of days with respiratory tract infections during the overall study period

    Negative binomial or Poisson regression with 95% CI.

    Time frame: Throughout the 7-month study period (3-month treatment + 4-month follow-up).

  3. Number of days of antibiotics use during the overall study period

    Estimated incidence rate ratio (IRR) using negative binomial regression (or Poisson if appropriate) with 95% CI.

    Time frame: Throughout the 7-month study period (3-month treatment + 4-month follow-up).

  4. Total number of workdays lost by parents due to their child's respiratory infections during the overall study period.

    Total number of workdays lost by children's parents due to the child's respiratory infections during the overall study period (cumulative days) For each endpoint: mean (SD), median (IQR), and cumulative counts by treatment arm; primary between-group effect presented as an incidence rate ratio (IRR) with 95% CI (PMBL® vs placebo). Absolute mean difference and 95% CI will also be provided for interpretability

    Time frame: Throughout the study (3 month-treatment period and 4 month-follow-up)

  5. Number of physician consultations due to RTI or related complications.

    Number of physician consultations due to RTI or related complications during the overall study period (count) For each endpoint: mean (SD), median (IQR), and cumulative counts by treatment arm; primary between-group effect presented as an incidence rate ratio (IRR) with 95% CI (PMBL® vs placebo). Absolute mean difference and 95% CI will also be provided for interpretability

    Time frame: Throughout the study (3 month-treatment period and 4 month-follow-up)

  6. Number of antibiotic treatments (courses) for a respiratory event during the overall study period.

    Number of antibiotic treatments courses for a respiratory event during the overall study period (count of courses) For each endpoint: mean (SD), median (IQR), and cumulative counts by treatment arm; primary between-group effect presented as an incidence rate ratio (IRR) with 95% CI (PMBL® vs placebo). Absolute mean difference and 95% CI will also be provided for interpretability

    Time frame: Throughout the study (3 month-treatment period and 4 month-follow-up)

  7. Number of subjects with (serious) adverse event and (serious) adverse drug reaction

    Descriptive statistics: number and proportion of subjects experiencing events by type and severity Number and type of AEs, SAEs, and SARs during the study period

    Time frame: Throughout the study (3 month-treatment period and 4 month-follow-up)

07

Study locations

9 of 10 sites recruiting
  • Bio Zdrowie
    Bialystok, Poland
    Recruiting
  • In Vivo Sp. z o.o.
    Bydgoszcz, Poland
    Recruiting
  • Vitamed
    Bydgoszcz, Poland
    Recruiting
  • Centrum Nowoczesnych Terapii
    Krakow, Poland
    Recruiting
  • Comarch Healthcare S.A.
    Krakow, Poland
    Not yet recruiting
  • Linden Sp. z o.o. sp.k.
    Krakow, Poland
    Recruiting
  • Allergotest
    Lublin, Poland
    Recruiting
  • Medicome Sp. z o.o.
    Oświęcim, Poland
    Recruiting
  • Med - Polonia
    Poznan, Poland
    Recruiting
  • Alergo-Med Specjalistyczna Przychodnia
    Tarnów, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2027, 9 months after the start.

Of 29 phase 4 interventional studies under Respiratory Tract Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 51. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 11, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Apr 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07578012
Lead sponsor
Lallemand Pharma AG
Responsible party
Sponsor
First posted
May 11, 2026
Start date
Jun 1, 2026
Primary completion
Mar 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Bernard GOUT, PharmD, PhD
Contact
bgout@pharmndev.ch
+33776583905
Andrzej EMERYK, MD, PhD
principal investigator · University Children Hospital, Lublin, Poland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bacterial Lysates

Start the discussion